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Abstract
Background: Limited information is available regarding the clinical efficacy of azithromycin for the treatment of
enteric fever due to fluoroquinolone-resistant Salmonella Typhi and Salmonella Paratyphi among travelers returning
to their home countries.
Case presentation: We report a case of a 52-year-old Japanese man who returned from India, who developed a
fever of 39°C with no accompanying symptoms 10 days after returning to Japan from a 1-month business trip to
Delhi, India. His blood culture results were positive for Salmonella Paratyphi A. He was treated with 14 days of
ceftriaxone, after which he remained afebrile for 18 days before his body temperature again rose to 39°C with
no apparent symptoms. He was then empirically given 500 mg of azithromycin, but experienced clinical and
microbiological failure of azithromycin treatment for enteric fever due to Salmonella Paratyphi A. However, the
minimum inhibitory concentration (MIC) of azithromycin was not elevated (8 mg/L). He was again given ceftriaxone
for 14 days with no signs of recurrence during the follow-up.
Conclusion: There are limited data available for the treatment of enteric fever using azithromycin in travelers from
developed countries who are not immune to the disease, and thus, careful follow-up is necessary. In our case, the low
azithromycin dose might have contributed the treatment failure. Additional clinical data are needed to determine the
rate of success, MIC, and contributing factors for success and/or failure of azithromycin treatment for both Salmonella
Typhi and Salmonella Paratyphi infections.
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Background
Salmonella enterica Typhi and Salmonella enterica Para-
typhi A, B, and C are the causative pathogens of enteric
fever in tropical and subtropical countries such as southern
and southeast Asia and Africa [1], and fluoroquinolone-
resistant strains of Salmonella Typhi and Salmonella
Paratyphi A have recently emerged in these countries
[2]. In developed countries, these strains cause enteric
fever in travelers returning from the endemic areas [3].
Azithromycin and the third-generation cephalosporins
(e.g., ceftriaxone) are the drugs of choice for treatment
of fluoroquinolone-resistant Salmonella Typhi and Sal-
monella Paratyphi [4]. However, the azithromycin break-
points for Salmonella Typhi and Salmonella Paratyphi A
have not been defined by the Clinical and Laboratory
Standard Institutions (CLSI) or the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) cri-
teria [5,6]. The number of studies regarding the clinical
efficacy of azithromycin for the treatment of enteric
fever is still limited, and to our knowledge, all of them
were conducted in endemic areas [7-11]. Here, we report
a case of azithromycin treatment failure in a Japanese man
with Salmonella Paratyphi A infection who returned from
travel.
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Case presentation
A 52-year-old Japanese man developed a fever of 39°C
with no accompanying symptoms 10 days after returning
to Japan from a 1-month business trip to Delhi, India.
He presented to a local clinic 5 days after the fever de-
veloped. Blood cultures grew with Gram-negative rods
(GNR) after 3 days, which were subsequently identified
as Salmonella Paratyphi A with unknown antibiotic sus-
ceptibility. The patient was transferred to our hospital to
complete his 14-d therapy with ceftriaxone (2 g daily).
He was afebrile for 18 days following the completion of
the antibiotic therapy, after which his body temperature
rose to 39°C with no apparent symptoms. He presented
to our hospital on Day 3 of the second fever. A blood
culture was performed, and the patient was empirically
treated with oral azithromycin (500 mg daily) owing to a
suspected relapse of enteric fever. The patient was com-
pliant with the oral antibiotic regimen. As the blood cul-
ture results showed GNR growth in 2 days, he was
readmitted to our hospital for further treatment. We
continued azithromycin treatment under direct observa-
tion by the medical staff for a total of 7 days. GNR was
again identified as Salmonella Paratyphi A, which was
found to be susceptible to ceftriaxone (minimum inhibi-
tory concentration [MIC], 0.12 mg/L), resistant to nalidixic
acid, and showed decreased susceptibility to ciprofloxacin
(MIC, 0.5 mg/L). The MIC’s for azithromycin were 8 mg/L
and 16 mg/L, as determined in a reference laboratory using
the E-test (Biomerieux Co. Ltd., Tokyo, Japan) and broth
micro dilution (BMD), respectively.
Despite the uninterrupted 7 days of oral azithromycin
treatment under direct observation, the patient remained
febrile until the final day of the regimen. Another blood
culture was performed, and the treatment was switched
to ceftriaxone because of suspected azithromycin treat-
ment failure. The blood culture showed GNR growth,
which was again identified as Salmonella Paratyphi A
with the same MICs for ceftriaxone, ciprofloxacin, and
azithromycin as the initial culture results. Fluorodeoxyglu-
cose positron emission tomography (FDG- PET) showed
slightly thickened intestinal wall of the colon. However, no
other inflammatory focuses suggesting deep-seeded infec-
tion, such as abscesses and aortitis, were detected. The ab-
dominal ultrasound showed no intra-abdominal abscess on
the thickened intestinal wall. The patient defervesced on
Day 3 of ceftriaxone, and the result of the follow-up blood
culture performed on Day 4 of ceftriaxone therapy yielded
no growth. After completion of 14 days of antibiotic treat-
ment, the patient was discharged with no signs of recur-
rence during the follow-up.
Discussion
Enteric fever due to nalidixic acid-resistant Salmonella
Typhi and/or Salmonella Paratyphi A is generally treated
with ceftriaxone or azithromycin [12,13] with previous
reports demonstrating the efficacy of azithromycin in
the treatment of enteric fever [7-9]. Moreover, the prob-
ability of recurrence is < 3% when treated with azithromy-
cin compared to 3–6% when treated with ceftriaxone.
Therefore, treatment with azithromycin may be preferred
for quinolone-resistant Salmonella Typhi and Salmonella
Paratyphi A [8,14]. However, data are currently only avail-
able for endemic regions of enteric fever where immunity
to the disease may contribute to the high success rates.
To the best of our knowledge, there has only been few-
case reports of treatment failure with azithromycin for
Salmonella Paratyphi A. In one report, the MIC for azi-
thromycin was > 64 mg/L, which was assumed to be
azithromycin-resistant; however, the exact mechanism of
resistance has not been defined [15]. In another report, a
case of recurrent, multifocal Salmonella enterica serotype
Paratyphi A breast abscesses was presented which re-
lapsed despite surgery and multiple courses of antibiotics,
including co-trimoxazole and azithromycin [16]. Although
the bioavailability of oral azithromycin was reported to be
approximately 37%, which is lower than that for fluoroqui-
nolones, it has been suggested that the intracellular con-
centration of azithromycin is 50–100 times greater than
that in serum and that the bactericidal effect remains
stable regardless of a high MIC [17,18]. The recent CLSI
guidelines and the EUCAST criteria do not specify the
MIC for azithromycin when treating Salmonella Typhi or
Salmonella Paratyphi A [5,6]. However, the EUCAST
states that the wild-type isolates of Salmonella Typhi have
an MIC ≤ 16 mg/L [6]. In a study conducted in India, the
MIC distributions for Salmonella Typhi and Salmonella
Paratyphi A ranged from 0.0612 to 64 mg/L and from 1 to
32 mg/L, respectively, and the MIC90 values were 24 mg/L
for both serovars [19]. Recent report on MIC distribution
of typhoidal Salmonella isolates of returned travelers
showed that azithromycin MICs were 2–256 μg/mL
among the 354 isolates, and a minority of the S. Paratyphi
A isolates showed an MIC ≤ 8 mg/L [20].
In the present case, we experienced clinical and micro-
biological treatment failure with azithromycin for enteric
fever due to Salmonella Paratyphi A despite the fact that
the MIC for azithromycin was not elevated (8 mg/L by
E-test and 16 mg/L by BMD). Previous studies evaluated
the efficacy of azithromycin therapy used various regi-
mens as summarized in Table 1. Most of the dosages
used ranged from 10 mg/kg to 20 mg/kg. A review pub-
lished in 2005 recommends 8–10 mg · kg−1 · dose−1 azi-
thromycin for enteric fever caused by either Salmonella
Typhi or Salmonella Paratyphi A [12]. Owing to the pa-
tient’s weight (80 kg) at the time of admission, 500 mg
of azithromycin [13], which was 6.25 mg/kg, might have
been an inadequate dose when compared to previously
recommended doses. Further studies are necessary in
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Table 1 Reported efficacy of azithromycin for treatment of Salmonella Typhi and Salmonella Paratyphi
Author, year Country Patients population Azithromycin dose Body weights of
patients (kg)
Route of administration Efficacy MIC of isolates, g/L* References
Girgis, 1999 Egypt n = 36, mean age (range):
19.6 (18–30)
1 g/day on the first day,
followed by 500 mg/day
on the next 6 days
NA Oral Clinical cure rate: 100% BMD, MIC*90 (range): 8 (4–16) [9]
Butler, 1999 India n = 42, mean age (range):
26.2 (17–53)
500 mg/day for 7 days Mean 52.2
(range: 40–74)
Oral Clinical cure rate: 88%
(within 8 days), 100%
(within 14 days)
BMD MIC*90 (range): 16 (4–32) [7]
Chinh, 2000 Vietnam n = 44, mean age (range):
26.6 (15–68)
1 g/day for 5 days Mean 47.3
(range: 34–60)
Oral Clinical cure rate: 95.5% E-test, MIC90 (range): 8 (4–16) [10]






Oral Clinical cure rate: 82% E-test MIC90 (range): 16 (4–32) [8]






Oral Treatement failure: 9.3% E-test, MIC90 (range): 12 (4–16) [11]
Abbreviations: BMD broth microdilution, MIC Minimum inhibitory concentrations, NA data not available.


















terms of optimal route of administration, and appropri-
ate dose and duration especially among returned trav-
elers who are not immune to typhoid.
In this case, no infectious focus such as arteritis or ab-
scesses was detected by the PET-CT scan and abdominal
sonography. We suspected that the thickening of intes-
tinal wall of the colon might be due to the hypertrophy
of Peyer’s patches; one of the classic presentations ob-
served in cases of enteric fever due to Salmonella Typhi
or Salmonella Paratyphi [21].
Conclusions
There are limited data available for the treatment of enteric
fever using azithromycin in travelers from developed coun-
tries who are not immune to the disease, and thus, careful
follow-up is necessary. Additional clinical data are needed
to determine the rate of success, MIC, and contributing
factors for success and/or failure of azithromycin treatment
for both SalmonellaTyphi and Salmonella Paratyphi.
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